QuellTX
Florence Mehtar began their work experience in September 2021 as an Industrial Placement Student for UCB, where they worked in the Tissue Remodelling Group under the supervision of Dr. Cristina Ottone. Florence completed their placement in September 2022. In June 2023, they started working as a Research Associate at Quell Therapeutics.
Florence Mehtar pursued a degree in Pharmacology at the University of East London from 2019 to 2022.
This person is not in the org chart
QuellTX
4 followers
Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions.Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cellengineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.